WPL take FAR and Operator role in Senegal?, page-3

First 3 Last

Share
Profile

Follow
Tony999

6,097 Posts.

94

24/08/16

13:21

Post #: 18642561
Share

Originally posted by spiroserafini ↑

Given the state of WPL's business and the reserves base and the fact they have not had a win in a very long time in the open marketplace, its not impossible for WPL to make an offer for FAR. I must also mention, doing business in fossil fuels in Australia is becoming harder each day and more expensive.

To operate the Senegal JV is pure cream, you get paid 50% of all costs and we all know how costs are allocated within JV's. In reality a great number of your staff costs are paid for by others within the JV. JV financial audits are excruciatingly painful and I've not met a CFO that hasn't loved JV's when the company is the operator.

WPL as the Senegal JV operator for the next 30 to 50 years will be a once in a career decision for WPL's Board and Woodside CEO Peter Coleman and his management team. A 30-50 year income stream locked in at 2016 values on today's resource numbers. An outstanding proposition if I do say so myself.

If one paid $1.5 billion for FAR (MC$350M) a multiple of 5 at a oil price or US$48.00 imagine the return at an oil price of US$60 averaged over the next half century? Don't forget further upgrades will continue to arrive and grow the resource base.

FAR can't operate the JV, simply don't have the expertise, WPL do and they are cash rich.

In terms of FAR having a third party in the wings, they may have, however to operate an offshore oil business successfully this limits the options as to who this third party may be! Not all existing offshore oil operators have the space cash required for the 35% nor the desire to enter the area. With the North Sea declining may be somebody form this region is in the wings?

In summary, I wouldn't miss how this plays out for quids, it may be the takeover of the century and prove yet again, small exploration companies (FAR) find resources and big energy companies (WPL) bring them to market.

Expand

Its a no brainer yet most on here can't see it.
I really don't know what WPL are waiting for.
They have already fired one bet at the pot, now they have to go all in and everyone else will fold.

Just don't get too cute with the first bid.

FAR Price at posting: 7.9¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 12 more messages in this thread...

First 3 Last

Add FAR (ASX) to my watchlist

(20min delay)
Last 48.5¢		Change -0.005(1.02%)		Mkt cap ! $44.81M

Open	High	Low	Value	Volume
48.5¢	48.5¢	48.5¢	$4.85K	10K

Buyers (Bids)

No.	Vol.	Price($)
1	31741	48.5¢

Sellers (Offers)

Price($)	Vol.	No.
49.0¢	200000	1

View Market Depth

No.	Vol.	Price($)
1	31741	0.485
2	14999	0.480
1	10000	0.475
3	107553	0.470
1	50000	0.465

Price($)	Vol.	No.
0.495	1786	1
0.500	15000	1
0.510	25000	1
0.520	326386	5
0.530	101005	2

Last trade - 10.04am 07/10/2024 (20 minute delay)

FAR (ASX) Chart

WPL take FAR and Operator role in Senegal?, page-3

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

WPL take FAR and Operator role in Senegal?, page-3

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News